Innervace Secures Up To $40 Million To Advance Novel Regenerative Medicine Platform For Neurological Disorders
Amount Raised
$40 Million
Round Type
Funding Round
Description
Innervace, a regenerative medicine company developing the first implantable biofabricated neural pathway to restore brain circuitry, announced today it has raised up to $40 million in Series A financing. The new funding led by Deerfield Management with participation from founding investor IP Group, Inc., in addition to Penn Medicine, WARF Ventures, and BioAdvance will accelerate efforts to develop Innervace’s lead program, which aims to reconstruct the lost nigrostriatal pathway in patients with Parkinson’s Disease. Additionally, this round of funding enables licensing of a cell source with a specific (A9) dopaminergic phenotype from a research collaboration between UC San Diego and Deerfield Management. Using these cells and a biofabricated scaffold pathway reconstruction strategy differentiates Innervace’s approach from current cell therapy approaches for Parkinson’s.
Quick answer
Innervace raised $40 Million in a Funding Round round, dated September 8, 2022. Innervace is based in New York, New York, United States.
- How much did Innervace raise?
- Innervace raised $40 Million in a Funding Round round on September 8, 2022.
- What does Innervace do?
- Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury.
- Where is Innervace based and how big is it?
- Innervace is based in New York, New York, United States.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Innervace that raised within 45 days of this round, from Fundz verified event records.
- Taysha Gene Therapies, Inc. raised $30M on October 21, 2022.
- Bectas Therapeutics raised $4.2M (Seed) on October 21, 2022.
- Akelos raised $6K (Seed) on October 21, 2022.
- nference raised $2.7M (Seed) on October 21, 2022.
- CathBuddy raised $6.2M (Seed) on October 21, 2022.
- Flow Pharma raised $180K (Seed) on October 20, 2022.
Who to call at Innervace, and when
A new round usually means Innervace is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Innervace raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Innervace, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Innervace. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Innervace raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Innervace raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.